Six-Month Results from the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment

Journal of Endovascular Therapy

Volumn 24, Issue 4, 2017, Pages 459-467

  Bausback, Yvonne ^a   Willfort Ehringer, Andrea ^b   Sievert, Horst ^c,d   Geist, Volker ^e   Lichtenberg, Michael ^f   Del Giudice, Costantino ^g   Sauguet, Antoine ^h   Diaz Cartelle, Juan ⁱ   Marx, Claudia ^j   Ströbel, Armin ^j   Schult, Ingolf ^k   Scheinert, Dierk ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c CardioVascular Center Frankfurt   (Germany)

^d ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

^e Heart Centre Bad Segeberg Hospital   (Germany)

^f Klinikum Arnsberg   (Germany)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h CLINIQUE PASTEUR   (France)

ⁱ BOSTON SCIENTIFIC CORPORATION   (United States)

^j CERES GmbH Evaluation and Research   (Germany)

^k Hemoteq AG   (Germany)

more..

Author keywords

drug coated balloon; drug eluting balloon; femoropopliteal segment; late lumen loss; paclitaxel; patency; peripheral artery disease; peripheral vascular diseases; popliteal artery; restenosis; stenosis; superficial femoral artery

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; BIOCOMPATIBLE COATED MATERIAL; CARDIOVASCULAR AGENT;

AGED; ANGIOGRAPHY; ARTICLE; CALCIFICATION; CONTROLLED STUDY; DRUG COATED BALLOON; DUAL ANTIPLATELET THERAPY; FEMALE; FEMOROPOPLITEAL BYPASS; FOLLOW UP; HUMAN; LEG ISCHEMIA; LIMB AMPUTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVASCULARIZATION; STENOSIS; SUPERFICIAL FEMORAL ARTERY; TARGET LESION REVASCULARIZATION; CLINICAL TRIAL; DEVICES; DIAGNOSTIC IMAGING; EQUIPMENT DESIGN; EUROPE; FEMORAL ARTERY; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; RECURRENT DISEASE; TIME FACTOR; TREATMENT OUTCOME; VASCULAR ACCESS DEVICE; VASCULAR PATENCY;

AGED; ANGIOPLASTY, BALLOON; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; EQUIPMENT DESIGN; EUROPE; FEMALE; FEMORAL ARTERY; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDIES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ACCESS DEVICES; VASCULAR PATENCY;

EID: 85026398684     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1177/1526602817710770     Document Type: Article

References (22)

1. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382: 1329-1340.
2. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992; 326: 381-386.
3. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007; 45 (suppl S): S5-S67.
4. Giacoppo D, Cassese S, Harada Y, et al. Drug-coated balloon versus plain balloon angioplasty for the treatment of femoropopliteal artery disease: an updated systematic review and meta-analysis of randomized clinical trials. JACC Cardiovasc Interv. 2016; 9: 1731-1742.
5. Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011; 4: 495-504.
6. Müller-Hülsbeck S, Keirse K, Zeller T, et al. Twelve-month results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease. J Endovasc Ther. 2016; 23: 701-707.
7. Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012; 5: 831-840.
8. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014; 7: 10-19.
9. Tepe G, Laird J, Schneider P, et al.IN.PACT SFA Trial Investigators. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and/or popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015; 131: 495-502.
10. Rosenfield K, Jaff MR, White CJ, et al.LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015; 373: 145-153.
11. Gongora CA, Shibuya M, Wessler JD, et al. Impact of paclitaxel dose on tissue pharmacokinetics and vascular healing: a comparative drug-coated balloon study in the familial hypercholesterolemic swine model of superficial femoral in-stent restenosis. JACC Cardiovasc Interv. 2015; 8: 1115-1123.
12. Granada JF, Stenoien M, Buszman PP, et al. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart. 2014; 1: e000117.
13. Scheinert D, Schulte KL, Zeller T, et al. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015; 22: 14-21.
14. Dattilo R, Himmelstein SI, Cuff RF,. The COMPLIANCE 360 degrees trial: a randomized, prospective, multicenter, pilot study comparing acute and long-term results of orbital atherectomy to balloon angioplasty for calcified femoropopliteal disease. J Invasive Cardiol. 2014; 26: 355-360.
15. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990; 16: 199-208.
16. Brooks R,. EuroQol: the current state of play. Health Policy. 1996; 37: 53-72.
17. Ware J Jr, Kosinski M, Keller SD,. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34: 220-233.
18. SF-12v2 Health Survey. 2016. https://campaign.optum.com/optum-outcomes/what-we-do/health-surveys/sf-12v2-health-survey.html. Accessed August 3, 2016.
19. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008; 118: 1358-1365.
20. Schroeder H, Meyer DR, Lux B, et al. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study. Catheter Cardiovasc Interv. 2015; 86: 278-286.
21. Schoenhagen P, Ziada KM, Vince DG, et al. Arterial remodeling and coronary artery disease: the concept of "dilated" versus "obstructive" coronary atherosclerosis. J Am Coll Cardiol. 2001; 38: 297-306.
22. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007; 115: 2745-2749.